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ABSTRACT Burkholderia cenocepacia is an opportunistic Gram-negative bacterium
that causes serious respiratory infections in patients with cystic ﬁbrosis. Recently, we
discovered that B. cenocepacia produces the extracellular bacterial lipocalin protein
BcnA upon exposure to sublethal concentrations of bactericidal antibiotics. BcnA
captures a range of antibiotics outside bacterial cells, providing a global extracellular
mechanism of antimicrobial resistance. In this study, we investigated water-soluble
and liposoluble forms of vitamin E as inhibitors of antibiotic binding by BcnA. Our
results demonstrate that in vitro, both vitamin E forms bind strongly to BcnA and
contribute to reduce the MICs of norﬂoxacin (a ﬂuoroquinolone) and ceftazidime (a
-lactam), both of them used as model molecules representing two different chemi-
cal classes of antibiotics. Expression of BcnA was required for the adjuvant effect of
vitamin E. These results were replicated in vivo using the Galleria mellonella larva in-
fection model whereby vitamin E treatment, in combination with norﬂoxacin, signiﬁ-
cantly increased larva survival upon infection in a BcnA-dependent manner. To-
gether, our data suggest that vitamin E can be used to increase killing by
bactericidal antibiotics through interference with lipocalin binding.
IMPORTANCE Bacteria exposed to stress mediated by sublethal antibiotic concentra-
tions respond by adaptive mechanisms leading to an overall increase of antibiotic
resistance. One of these mechanisms involves the release of bacterial proteins called
lipocalins, which have the ability to sequester antibiotics in the extracellular space
before they reach bacterial cells. We speculated that interfering with lipocalin-
mediated antibiotic binding could enhance the efﬁcacy of antibiotics to kill bacteria.
In this work, we report that when combined with bactericidal antibiotics, vitamin E
contributes to enhance bacterial killing both in vitro and in vivo. This adjuvant effect
of vitamin E requires the presence of BcnA, a bacterial lipocalin produced by the
cystic ﬁbrosis pathogen Burkholderia cenocepacia. Since most bacteria produce li-
pocalins like BcnA, we propose that our ﬁndings could be translated into making
novel antibiotic adjuvants to potentiate bacterial killing by existing antibiotics.
KEYWORDS Gram-negative bacteria, antibiotic resistance, chronic infection, cystic
ﬁbrosis, intrinsic resistance, lipocalin, vitamin E
Antimicrobial resistance is an increasingly serious global health problem under-pinned by the emergence of opportunistic, multidrug-resistant bacteria (1–3). It is
imperative to ﬁnd new ways of treating bacterial infections, especially those caused by
Gram-negative pathogens (4). We recently discovered that the opportunistic bacterium
Burkholderia cenocepacia can resist antibiotics by mechanisms operating extracellularly
and induced in response to near-lethal antibiotic concentrations (5, 6). This means that
under chemotoxic stress, microbes can ﬁght antibiotics even before they reach bacte-
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rial cells. Key molecules involved in this mechanism are the polyamine putrescine and
bacterial lipocalins, a highly conserved group of -barrel-shaped proteins of unknown
function (YceI family) produced by more than 5,500 bacterial species (5, 7).
Gram-negative bacterial species belonging to the Burkholderia cepacia complex (8),
especially B. cenocepacia, are opportunistic pathogens that cause deleterious chronic
respiratory infections in patients with cystic ﬁbrosis (9, 10). Once established, infection
by B. cenocepacia is very difﬁcult to eradicate since these bacteria display high levels of
intrinsic antibiotic resistance to many different antibiotics (11, 12). We showed previ-
ously that B. cenocepacia secretes the extracellular bacterial lipocalin protein BcnA
(BCAL3311) upon challenge with different classes of bactericidal antibiotics (5, 7).
Lipocalins are a functionally diverse family of small ligand-binding proteins that are
common to many organisms, from bacteria to humans (13, 14), and which share a
conserved -barrel architecture (15). Both BcnA and other bacterial lipocalins from
different pathogens such as Pseudomonas aeruginosa, Mycobacterium tuberculosis, and
Staphylococcus aureus, heterologously expressed in B. cenocepacia, contribute to aug-
ment multidrug antibiotic resistance in vitro and in vivo (7). Further, antimicrobial
peptides (e.g., polymyxin B and colistin) and other bactericidal antibiotics (e.g., rifam-
pin, norﬂoxacin, and ceftazidime) can displace the hydrophobic probe Nile Red bound
to puriﬁed BcnA, suggesting that this lipocalin binds to a range of bactericidal antibi-
otics (7).
Liposoluble vitamins E (-tocopherol) and K2 (menaquinone) can overcome antibi-
otic resistance mediated by bacterial lipocalins (7), but the mechanism of inhibition was
not fully elucidated. We hypothesized that vitamin E reduces antimicrobial resistance
by binding to BcnA with higher afﬁnity than antibiotics, thus suppressing the contri-
bution of BcnA to antibiotic resistance. In this study, we investigated the mechanism by
which vitamin E sensitizes B. cenocepacia to several different antibiotics. We show that
both liposoluble and water-soluble forms of vitamin E, in combination with antibiotics,
signiﬁcantly reduce the MIC levels of several bactericidal antibiotics against B. cenoce-
pacia. Further, the potentiating ability of vitamin E on antibiotics requires BcnA since it
is not manifested in mutants unable to produce the lipocalin. Using the wax moth
Galleria mellonella infection model, we also demonstrate that treatment with vitamin E
and antibiotics after infection resulted in increased survival of infected Galleria larvae,
suggesting that vitamin E has an adjuvant effect that enhances the effectiveness of
various bactericidal antibiotics.
RESULTS
bcnA is part of a three-gene operon. B. cenocepacia K56-2 produces two lipocalin
homologues, BcnA (BCAL3311) and BcnB (BCAL3310), of which only BcnA is secreted to
the extracellular space and is primarily involved in conferring increased antimicrobial
resistance (5, 7). Both bcnA and bcnB genes in B. cenocepacia are linked to an upstream
gene encoding a predicted membrane cytochrome b561 protein (BCAL3312), which we
have annotated as bcoA (bcnA cytochrome oxidase-associated gene). bcnA and bcoA are
commonly linked loci in many bacterial genomes (e.g., Pseudomonas aeruginosa and
Salmonella). The genomic organization of the bcn region in B. cenocepacia suggests that
bcoA, bcnA, and bcnB are cotranscribed (7). To determine if these is the case, we
performed RT-PCR assays using primers spanning gene sequences and intergenic
regions of these three genes (Fig. 1; see also Table S1 in the supplemental material).
PCR ampliﬁcation of the cDNA templates gave amplicons of the expected sizes com-
parable to genomic DNA (Fig. 1), while PCR using the negative control failed to give any
detectable ampliﬁcation, indicating that the cDNA samples were clear of genomic DNA
contamination (Fig. 1A, lanes 2). These results indicate that bcoA, bcnA, and bcnB form
a three-gene operon in B. cenocepacia (Fig. 1B).
The effect of vitamin E on B. cenocepacia antibiotic resistance depends on the
BcnA protein. We previously reported that BcnA increases multidrug antibiotic resis-
tance in B. cenocepacia by sequestering bactericidal antibiotics in the extracellular
milieu, a property that could be inhibited by liposoluble vitamins like vitamins E and K2
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(7). To better characterize the effect of vitamin E on selected antibiotic molecules in the
presence or absence of BcnA expression, we performed checkerboard assays using
D--tocopheryl polyethylene glycol 1000 succinate (TPGS) and several bactericidal
antibiotics. In contrast to authentic vitamin E (-tocopherol), TPGS is a water-soluble
vitamin E derivative that arises from the esteriﬁcation of D--tocopheryl succinate with
polyethylene glycol (16). We used norﬂoxacin (a ﬂuoroquinolone), ceftazidime (a
-lactam), and polymyxin B (an antimicrobial peptide) as model bactericidal antibiotics
whose activity is affected by BcnA (7). Checkerboard assays demonstrated that 0.7 mM
was the most effective concentration of TPGS to work in combination with the
antibiotics.
When TPGS was given together with norﬂoxacin, there was an 8-fold reduction in
the MIC of the parental strain to the antibiotic (MIC of 8 2 g/ml), compared to
bacteria exposed to only norﬂoxacin (MIC of 64 15 g/ml; P 0.004), while TPGS had
no effect on the norﬂoxacin MIC values (8.5 1.2 g/ml) of the ΔbcnAmutant (Fig. 2A).
The lower norﬂoxacin MIC values for the ΔbcnA mutant reﬂect the reduction in
antibiotic resistance associated with the loss of BcnA and in the case of norﬂoxacin are
8-fold lower than in the parental (bcnA) strain (7) and comparable to the MIC of the
parental strain in the presence of TPGS. These results indicate that TPGS can reduce the
norﬂoxacin MIC values to similar levels as found in the absence of the bcnA gene,
suggesting that TPGS directly inhibits BcnA functionality. We also evaluated the role of
the other proteins encoded by the bcoA-bcnAB operon. The MIC of norﬂoxacin against
the ΔbcnB mutant (64 10.5 g/ml) was reduced to 32 7.4 g/ml when combined
with TPGS (P 0.02). Similar results were obtained with norﬂoxacin-TPGS against the
ΔbcoA mutant, where the MIC decreased from 32 5.2 g/ml to 16 3 g/ml
(P 0.01) (Fig. 2A). It should be noted that all these mutants were constructed as
unmarked nonpolar deletions (7) and therefore contain a functional bcnA gene, which
explains the lesser effect on MIC values. However, the minor reduction in MIC shown by
the ΔbcoAmutant may be attributable to the absence of the predicted cytochrome b561
protein encoded by this gene. The ΔbcnAB and ΔbcnAB ΔbcoA combination mutants
had increased sensitivity to norﬂoxacin alone (MICs of 32 7.4 and 8 2 g/ml,
respectively) (Fig. 2A), and TPGS had no additional effect in reducing these values even
further (Fig. 2A), supporting the notion that the TPGS effect is clearly noticeable in the
presence of BcnA. Similar results were obtained with ceftazidime (Fig. 2B). In this case,
all isolates producing BcnA (strain K56-2 and the ΔbcnB and ΔbcoA mutants) had MIC
values of 288, 256, and 256 g/ml, respectively, which were 4-fold reduced in combi-
nation with TPGS. As with norﬂoxacin, addition of TPGS had no effect on the MIC
against mutants with bcnA gene deletions. Therefore, TPGS can contribute to the
reduction of MIC levels of two different antibiotics in a BcnA-dependent manner.
FIG 1 bcoA, bcnA, and bcnB form an operon. (A) PCR ampliﬁcation using cDNA and gDNA templates
derived from B. cenocepacia K56-2. Lanes: M, 100-bp ladder; 1, gDNA-derived PCR product; 2, negative
control (no RT during cDNA synthesis); 3, cDNA-derived PCR product. All samples were run in the same
gel; the dotted white lines are for clarity only. (B) Intragenic amplicons are in black; intergenic regions are
in red. The direction of transcription is indicated. Primers and PCR amplicon positions from panel A are
indicated by the black (intragenic regions) and blue (intergenic regions) arrow pairs.
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We performed complementation experiments to conﬁrm if the observed results
were related to the presence of a functional bcnA gene. The genetically complemented
ΔbcnA, ΔbcnAB, and ΔbcnAB ΔbcoA strains, all carrying a plasmid expressing BcnA,
exhibited increased antibiotic resistance (mean MICs of norﬂoxacin of 48, 96, and
112 g/ml and mean MICs of ceftazidime of 384, 384, and 448 g/ml, respectively)
(Fig. 2C and D). However, the complemented strains had reduced MIC values for
norﬂoxacin and ceftazidime (by approximately 2-fold) when they were treated with
1.4 mM TPGS and antibiotics (Fig. 2C and D), demonstrating that TPGS works through
BcnA. We interpreted the higher concentration of TPGS required in these experiments
as a consequence of the overexpression of BcnA from a plasmid instead of from the
native promoter at the chromosomal location of the bcnA gene.
The observed results did not depend on the vitamin E formulation since liposoluble
vitamin E (at 0.2 mM) in combination with norﬂoxacin also resulted in increased
antibiotic activity when the treated strains expressed BcnA or in mutants genetically
complemented by introducing the BcnA-encoding plasmid (Fig. S1). Because BcnA
becomes important when B. cenocepacia is exposed to subinhibitory concentrations of
bactericidal antibiotics (5, 7), we also evaluated the effect of TPGS in bacteria exposed
to sub-MIC antibiotic concentrations using in this case norﬂoxacin and polymyxin B.
Subinhibitory antibiotic concentrations were deﬁned as 25% of the MIC (MIC25) for each
FIG 2 Vitamin E antibiotic adjuvant effect depends on the BcnA protein. (A) MIC of norﬂoxacin alone or
in combination with 0.7 mM TPGS against Burkholderia strains, determined by broth microdilution in
cation-adjusted Mueller-Hinton broth (MHB) at 24 h. Data points are from 4 independent experiments,
each done in duplicate (n  8). (B) MIC of ceftazidime alone or combined with TPGS against Burkholderia
strains in MHB at 24 h (n  4, from 2 independent experiments). (C) MIC of norﬂoxacin alone or mixed
with 1.4 mM TPGS against ΔbcnA mutants carrying pDA17 and ΔbcnA mutants harboring pDA17 bcnA,
determined by broth dilution methods in MHB at 24 h (n  4, from 2 independent experiments). (D) MIC
of ceftazidime alone or mixed with 1.4 mM TPGS against ΔbcnA mutants carrying pDA17 and ΔbcnA
mutants harboring pDA17 bcnA at 24 h (n  4, from 2 independent experiments). Results are shown as
the mean MIC  SEM, and P values were calculated by the paired t test.
Naguib and Valvano
November/December 2018 Volume 3 Issue 6 e00564-18 msphere.asm.org 4
 o
n
 January 16, 2019 by guest
http://m
sphere.asm
.org/
D
ow
nloaded from
 
of the strains used (ranging from 2 to 16 g/ml), and surviving bacteria were enumer-
ated after challenge with norﬂoxacin and polymyxin B for 2 and 6 h, respectively.
Norﬂoxacin and TPGS in combination caused around a 50% reduction in the number of
surviving K56-2 bacteria, compared to norﬂoxacin alone (Fig. 3A). Similar results were
obtained by challenging the ΔbcnB and ΔbcoA mutant strains (Fig. 3C and E). On the
other hand, ΔbcnA, ΔbcnAB, and ΔbcnAB ΔbcoA strains showed nearly the same number
of bacterial counts as in the norﬂoxacin challenge alone either in the absence or in the
presence of TPGS (Fig. 3B, D, and F). The effect of the antibiotic alone or in combination
with TPGS also resulted in signiﬁcant growth rate reduction over time for the parental
K56-2 strain treated with norﬂoxacin (at MIC25) and TPGS compared to treatment with
norﬂoxacin only (Fig. S2A). In contrast, the ΔbcnA mutant treated with norﬂoxacin and
TPGS showed no difference in growth rate from treatment with antibiotic alone
(Fig. S2B). Challenge experiments with polymyxin B at 256 g/ml (MIC25) and TPGS for
2 h did not show any differences among the strains, likely due to their high level of
intrinsic resistance to polymyxin B. However, challenge up to 6 h revealed a signiﬁcant
reduction in the number of surviving bacteria relative to challenge with polymyxin B
alone for the parental K56-2 and the ΔbcnB and ΔbcoA mutant strains (Fig. 3G, I, and
K) but no signiﬁcant changes in the absence of BcnA protein, irrespective of the
addition of TPGS (Fig. 3I, J, and L).
Together, the combined results of the experiments in this section demonstrate that
vitamin E, in either soluble or liposoluble forms, exerts an adjuvant effect enhancing the
bactericidal activity of different antibiotics in a BcnA-dependent manner.
Vitamin E prevents BcnA antibiotic binding. To determine the mechanism of the
vitamin E antibiotic adjuvant effect, we performed chemical complementation exper-
iments in which 1.5 M puriﬁed BcnA was added to the various ΔbcnA mutants in the
presence or absence of the antibiotic and with or without TPGS. The chosen amount of
BcnA was the minimal protein concentration that gives an effect in Galleria mellonella
and mouse infections, as described previously (7). Exogenously added BcnA protein
conferred increased norﬂoxacin resistance to ΔbcnA, ΔbcnAB, and ΔbcnAB ΔbcoA
mutants (MIC values of 64, 76, and 32 g/ml, respectively), but this effect was abolished
in the presence of TPGS, resulting in MICs of 8 g/ml for the three strains (P 0.02)
(Fig. 4). Similar results were also obtained using the ΔbcnA mutant treated with
norﬂoxacin, 0.2 mM liposoluble vitamin E, and 1.5 M BcnA protein; the MIC decreased
from 32 11.31 g/ml to 4 0 g/ml (P 0.04). In this experiment, the MIC of nor-
ﬂoxacin was reduced by 8-fold compared to the treatment with BcnA protein only
(P 0.04). Together, these experiments support the idea that TPGS and liposoluble
vitamin E interact with BcnA protein directly and prevent antibiotic capture by BcnA.
Binding of TPGS and norﬂoxacin to BcnA was investigated by isothermal titration
microcalorimetry (ITC), a bioanalytical technique that provides the thermodynamics
parameters of the interactions between molecules by measuring the dissipated or
absorbed heat upon the binding event, allowing the calculation of association and
dissociation (KD) constants and the enthalpy (ΔH°) and entropy (ΔS°) of the interaction
(17–19). The binding properties of TPGS toward BcnA indicated a KD of nearly 6 Mwith
a stoichiometry (N value) approaching 1 (0.73) (Fig. 5C), indicating the binding of one
monomer of BcnA per TPGS molecule, which is also in agreement with the hyperbolic
shape of the titration thermogram (Fig. 5A). The calculated negative ΔH° and positive
ΔS° values of the TPGS-BcnA interaction suggested that strong electrostatic interactions
play a key role in binding, and the ΔG° of 7.876 kcal indicates that the binding
reaction is favorable and spontaneous. The binding properties of norﬂoxacin toward
BcnA showed a KD of 4.9 mM, with a stoichiometry of 0.77 (Fig. 5C), denoting also the
binding of one monomer of BcnA per norﬂoxacin molecule. In contrast to the titration
thermogram for TPGS, the thermogram for norﬂoxacin corresponded to an endother-
mic binding interaction with BcnA (Fig. 5B). A positive ΔH° (Fig. 5C) usually indicates
that the complex formation between norﬂoxacin and BcnA is mainly driven by hydro-
phobic interactions (20, 21). Indeed, hydrogen bonding has been proposed as a
Vitamin E Enhances Antibiotic Killing
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FIG 3 Antibiotic challenge assays. Burkholderia strains were challenged with MIC25 of norﬂoxacin, which varied for each
strain (16 g/ml for the parental strain K56-2 and the ΔbcnB strain, 8 g/ml for ΔbcnAB and ΔbcoA strains, and 2 g/ml
for ΔbcnA and ΔbcnAB ΔbcoA strains) with or without 0.7 mM TPGS (A to F) in cation-adjusted MHB for 2 h at 37°C. For
challenge with polymyxin B, bacteria were exposed to MIC25 (256 g/ml of polymyxin B for all strains), with or without
0.7 mM TPGS (G to L), using non-cation-adjusted MHB for 6 h at 37°C. (A and G) Wild-type K56-2; (B and H) ΔbcnA strain;
(C and I) ΔbcnB strain; (D and J) ΔbcnAB double mutant; (E and K) ΔbcoA strain; (F and L) ΔbcnAB ΔbcoA triple mutant.
Results are shown as the mean MIC  SEM, by determining the CFU of surviving bacteria. P values were calculated by
the paired t test. Data represent the results of 3 independent experiments, each done in duplicate (n  6).
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mechanism for the binding of norﬂoxacin to activated carbon nanotubes (22) and
polydopamine microspheres (23). The calculated dissociation binding constant for
TPGS-BcnA was approximately 800-fold higher than that of norﬂoxacin-BcnA (Fig. 5C),
consistent with the high concentration of norﬂoxacin required to detect binding to
BcnA. Together, these results agree with previously reported molecular dynamics
studies showing that norﬂoxacin weakly binds BcnA at the ﬂexible loops in the rim of
the BcnA cavity (7). Therefore, the chemical complementation experiments and the
direct binding assays demonstrate that BcnA binds strongly to vitamin E and this
high-afﬁnity interaction prevents the much weaker BcnA antibiotic binding.
Vitamin E treatment enhances in vivo survival of Burkholderia-infected G.
mellonella larvae. We reported previously that coadministration of BcnA and Burk-
holderia to G. mellonella larvae increases the bacterial load and reduces larvae survival.
Because infected G. mellonella larvae mount a cellular and humoral response charac-
terized by the production of multiple antimicrobial peptides (24, 25), these results
suggested that BcnA can bind and neutralize antimicrobial peptides (in a similar way as
polymyxin B). We employed the G. mellonella infection model to probe the effect of the
BcnA-inhibitory activity of TPGS after infection with the parental strain and the ΔbcnA
mutant using a dose of 8 103 CFU for each strain. At 48 h postinfection, both the
parental K56-2 strain and the ΔbcnA mutant chemically complemented by coinjection
of 1.5 M BcnA caused great mortality resulting in less than 20% larva survival and no
larvae surviving at 72 h (Fig. 6A). As expected, the control experiment using the ΔbcnA
strain showed survival rates of 45% and 40% at 48 and 72 h, respectively (Fig. 6A).
Administering 0.7 mM TPGS together with the bacterial inoculum enhanced survival up
to 90% and 80% at 48 and 72, respectively, in larvae infected with either K56-2 or the
ΔbcnA strain plus BcnA protein (Fig. 6A). In contrast, the survival of larvae infected with
the ΔbcnA strain was not signiﬁcantly improved by coadministration of TPGS in
comparison to infection with the ΔbcnA strain only. Analysis of the bacterial loads
recovered from the larvae’s hemolymph at 48 h demonstrated that K56-2 bacterial CFU
decreased up to 6 log in the presence of TPGS compared to the bacterium-only
infection (Fig. 6B). Similar results were obtained with the chemically complemented
mutant bacteria in the presence of TPGS, while no signiﬁcant difference was observed
in the bacterial counts of larvae infected with the ΔbcnA strain in the presence or
absence of TPGS (Fig. 6B).
We also investigated if the norﬂoxacin-TPGS combination can be applied as a
treatment for previously infected G. mellonella larvae. For this experiment, larvae were
infected with 100 CFU of the parental K56-2 strain or the ΔbcnA mutant, and treatment
with norﬂoxacin only, TPGS only, or norﬂoxacin plus TPGS was given at 24 h postin-
FIG 4 In vitro protection assays against norﬂoxacin with 1.5 M BcnA protein in the absence or presence
of 0.7 mM TPGS. The results were obtained from 4 independent experiments, each in duplicate (n  8),
and plotted as the mean MIC  SEM. **, P 0.02 determined by paired t test.
Vitamin E Enhances Antibiotic Killing
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fection. Compared to norﬂoxacin- or TPGS-only treatments, the survival of K56-2-
infected larvae increased to more than 80% upon treatment with norﬂoxacin and TPGS
(Fig. 7A), and this correlated with at least a 3-log reduction in the bacterial load (Fig. 7B).
In contrast, the combination of norﬂoxacin and TPGS did not protect larvae against
infection with the ΔbcnA strain (Fig. 7C and D). These results indicate that TPGS can
improve the in vivo efﬁcacy of an antibiotic in a BcnA-dependent manner.
Vitamin E increases antibiotic susceptibility in P. aeruginosa. To investigate if
the adjuvant effect of TPGS can be applicable to other bacterial species, we performed
in vitro and in vivo experiments using the classical P. aeruginosa PAO1 strain. In vitro, the
combination of norﬂoxacin and ceftazidime with 1.4 mM TPGS showed signiﬁcant
reduction (over 3-fold) in the MICs of both antibiotics against the strain PAO1 in
comparison to the MICs for the antibiotic-only treatments (Fig. 8A). We also performed
the treatment of infected larvae using norﬂoxacin or the combination of norﬂoxacin
and TPGS. Because strain PAO1 is highly virulent for G. mellonella, we used an inoculum
of 10 CFU and performed the treatments at 2 h postinfection, which gives sufﬁcient
time to establish an infection (26). A statistically signiﬁcant difference was seen be-
tween the survival of untreated larvae and that of larvae treated with norﬂoxacin and
FIG 5 Binding analyses by microcalorimetry. (A and B) ITC data of TPGS binding to BcnA (A) and the presence of norﬂoxacin
(B). The bottom panel shows that the binding isotherm is obtained by plotting the areas under the peaks in the top panel
against the molar ratio of ligand (TPGS or norﬂoxacin) added to BcnA present in the cell. (C) Physicochemical binding
parameters of TPGS and norﬂoxacin to BcnA. The binding afﬁnity (K) and enthalpy change (ΔH°) were obtained from ITC
proﬁles ﬁtting to “one set of binding sites” modeled by Origin 7 software. ΔG° and TΔS° were determined by the equations
ΔG°   RT lnK and TΔS°  ΔH°  ΔG°. N is the binding stoichiometry. KD is the dissociation constant. The data presented
are the average from two experiments.
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TPGS together (Fig. 8B). Similar results were obtained, as expected, in the control
experiments using larvae infected with the B. cenocepacia K56-2 strain at a dose of 10
bacterial cells per larva. In this case, while the survival rate of untreated G. mellonella
was 30%, more than 80% survival was obtained in larvae treated with norﬂoxacin and
TPGS (Fig. 8B). Therefore, these results support the notion that the beneﬁt of vitamin
E as antibiotic adjuvant treatment is not speciﬁc to B. cenocepacia.
DISCUSSION
We have recently established that production and secretion of the bacterial lipocalin
BcnA, especially from bacteria exposed to near-lethal antibiotic concentrations, provide
B. cenocepacia and other Gram-negative bacteria an additional mechanism of resistance
against different classes of bactericidal antibiotics (5, 7). Increased resistance is based
on the ability of BcnA to scavenge antibiotics in the extracellular milieu. In this study,
we demonstrate that BcnA binding to water-soluble and liposoluble forms of vitamin
E increases bacterial susceptibility to antibiotics both in vitro and during infection using
the G. mellonellamodel. We found that the potentiating effect of vitamin E on antibiotic
activity occurs only in bacteria that produce BcnA but not in mutants lacking the bcnA
gene. We further show that vitamin E binds directly to the puriﬁed B. cenocepacia BcnA
lipocalin with an afﬁnity in low nanomolar concentrations, while the model antibiotic
norﬂoxacin binds with an afﬁnity in the micromolar level. These results agree with
previous molecular docking predictions indicating that the alkyl chain of liposoluble
vitamin E is buried into the BcnA -barrel tunnel and that its cyclic head is placed
toward the entrance of the tunnel (7). Therefore, we conclude that vitamin E-bound
FIG 6 In vivo protection assays using G. mellonella infection model. (A) Larvae were infected with 8 103
CFU of B. cenocepacia K56-2, ΔbcnAmutant, and ΔbcnAmutant plus 1.5 M BcnA protein in the presence
or absence of 0.7 mM TPGS. Larva survival was monitored over 72 h postinfection. (B) Hemolymph from
at least three B. cenocepacia-infected larvae was extracted and pooled at 48 h postinfection to determine
the bacterial CFU/ml by plating onto LB agar containing 200 g/ml spectinomycin (to prevent the
growth of the larvae’s endogenous microbial ﬂora agar. The results represent the mean and the SEM from
3 independent biological replicates. ***, P  0.001.
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BcnA results in a net increase of free antibiotic concentration, explaining both the
increased antibiotic susceptibility and the dependence on BcnA for this phenotype.
In addition to authentic vitamin E, we employed here TPGS, a succinylated poly-
ethylene glycol-bound derivative of vitamin E that retains the same properties of
-tocopherol but is water soluble. Water solubility allows for more reproducible
quantitative experimental conditions. Further, TPGS is already used in the pharmaceu-
tical industry as a wetting, emulsiﬁcation, solubilization, and spreading agent (16, 27).
TPGS can solubilize water-soluble and lipophilic molecules, forming various types of
micelles (28) and increasing the solubility of drugs like cyclosporines, taxanes, steroids,
and antibiotics (reviewed in reference 16). Administration of vitamin E has been
reported to enhance antibiotic activity, but the mechanism appears to be indirect. For
example, administration of vitamin E prior to infection improves the in vivo efﬁcacy of
antibiotics in wounds experimentally infected with methicillin-resistant S. aureus (29)
due to a general improvement in immunological parameters. Similarly, vitamin E
administration reduces inﬂammation in a rat model of Escherichia coli pyelonephritis
(30) and in a Streptococcus pneumoniae lung infection model (31). In contrast, our data
demonstrate that the antibiotic adjuvant effect of vitamin E and TPGS, at least in B.
cenocepacia and P. aeruginosa, is associated with the presence of a functional BcnA
FIG 7 Treatment of G. mellonella-infected larvae with norﬂoxacin or norﬂoxacin plus TPGS in combination
with the wild type or ΔbcnA mutant. Larvae were infected with 100 CFU of bacteria for 24 h and then
treated with the MIC of norﬂoxacin appropriate to each bacterial strain with or without 1.7 mM TPGS.
Percent survival and the bacterial load (CFU/ml) in the larva’s hemolymph were determined at 48 h
postinfection. The results represent the mean and SEM for 3 biological repeats. (A and B) Percent survival
and bacterial load, respectively, of larvae infected with the parental K56-2 strain. (C and D) Percent survival
and bacterial load, respectively, of ΔbcnA strain-infected larvae.
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protein, thus revealing a previously unappreciated connection between a bacterial
lipocalin and vitamin E binding.
Vitamin E is considered the main antioxidant in biological membranes (32), and
many of its beneﬁcial effects in immunoregulation (33) are attributed to its radical
scavenging activity in lipophilic environments, resulting in the stabilization of polyun-
saturated fatty acids in membrane lipids. At the same time, the physical properties of
vitamin E make this molecule and its derivatives useful carriers for drug delivery in
general (16) and for pulmonary drug delivery in particular (34–36). Given our results, it
might be feasible to consider including vitamin E in antibiotic formulations delivered by
nebulization to patients with cystic ﬁbrosis to increase their efﬁcacy. In summary, we
conclude that vitamin E acts as a lipocalin antibiotic binding inhibitor, helping to
increase the effective concentration of antibiotics around bacterial cells, suggesting
that vitamin E could be used as an antibiotic adjuvant in combination with antibiotics
for the treatment of infections caused by multidrug-resistant Burkholderia and other
similar multidrug-resistant bacteria.
MATERIALS AND METHODS
Strains and reagents. The bacterial strains and plasmids used in this study are listed in Table S1 in
the supplemental material. Bacteria were cultured in Mueller-Hinton broth (MHB) or Luria Broth (LB) at
37°C. Antibiotics (Sigma-Aldrich, United Kingdom) were diluted in water, except for polymyxin B, which
was diluted in 0.2% bovine serum albumin with 0.01% acetic acid. TPGS (Sigma-Aldrich, United Kingdom)
was dissolved in water at a concentration of 140 mM. Liposoluble -tocopherol (vitamin E; Sigma-Aldrich,
United Kingdom) was dissolved in dimethyl sulfoxide (DMSO).
Molecular biology methods. Genomic DNA was extracted from 1-ml overnight bacterial cultures
suspended in LB. After centrifugation, bacterial pellets were resuspended in 400 l lysis buffer containing
sodium dodecyl sulfate (SDS) and incubated at room temperature for 10 min. Protein and cell debris were
precipitated by adding 200 l NaCl and incubating in ice for 20 min, followed by centrifugation at
4,000 rpm for 15 min. The supernatant was precipitated with absolute ethanol and centrifuged, and the
DNA pellets were resuspended in diethylpyrocarbonate (DEPC)-treated deionized water. All procedures
were carried out using DEPC-treated water. Genomic DNA (gDNA) samples were stored at 20°C. RNA
was extracted and puriﬁed using the RNeasy Mini Plus kit (Qiagen), as indicated by the manufacturer.
RNA samples were treated with 5 l of DNase, and 5 l of 10 DNase buffer (Turbo DNA Free) was added
to 40 l of RNA in a 1.5-ml Eppendorf tube. Reaction mixtures were incubated at 37°C for 1.5 h, and
reactions were terminated by adding 10 l DNase inactivation reagent followed by incubation for 5 min
at room temperature. DNase-treated samples were centrifuged for 5 min, and the supernatant containing
the RNA was stored at 80°C. Purity and quality of the RNA samples were determined by agarose gel
electrophoresis using 1% agarose gels supplemented 1:10 with Midori green. Also, RNA samples were
screened for gDNA contamination after DNase treatment by PCR with 16S control primers. cDNA
synthesis was carried out using the RevertAid kit according to the manufacturer’s instructions. This kit
allows for initial priming of RNA samples with random primers followed by cDNA synthesis. The initial
step allows for degradation of RNA secondary structure prior to reverse transcription. cDNA samples were
kept at 20°C until used. PCRs were carried out with the Dream Taq PCR Master Mix (ThermoFisher
Scientiﬁc), and the primer pairs are listed in Table S1.
FIG 8 Vitamin E can reduce the antibiotic resistance of P. aeruginosa PAO1. (A) MIC of norﬂoxacin and ceftazidime with and without
1.4 mM TPGS against PAO1 using microdilution method at 24 h (n  4, from 2 independent experiments and 2 biological replicates).
Results are shown as the mean MIC SEM and compared using the paired t test. (B) Norﬂoxacin-TPGS treatment of G. mellonella larvae
infected with 10 CFU of P. aeruginosa PAO1 or B. cenocepacia K56-2 for 2 h and then treated with the MIC of norﬂoxacin, 1.7 mM TPGS,
or the two together. Percentage of larva survival was monitored after 24 h. n  3. *, P  0.05; **, P  0.01.
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Puriﬁcation of BcnA protein. Escherichia coli BL21 bacteria harboring pET28a-bcnA were grown for
3 h with 500 mM isopropyl thio--galactoside (ThermoFisher Scientiﬁc, United Kingdom) at 25°C; bacteria
were harvested, resuspended in 50 mM phosphate buffer (PBS), pH 7.4 (Sigma-Aldrich, United Kingdom),
with protease inhibitors (Roche Diagnostic GmBH, Germany), and lysed using a cell disruptor at 27 kpsi
(Constant Systems). The lysate was cleared by centrifugation at 16,000 g for 60 min at 4°C (Sorvall RC
6 Plus, Germany), and the supernatant was ﬁltered through 0.2-m in-line ﬁlters. The supernatant was
passed through a HisTrap FF 5-ml column, using AKTA Start (GE Healthcare Bio-science, Sweden). The
puriﬁed protein was detected by Coomassie blue staining following 16% SDS-PAGE and quantiﬁed by
Bradford assay using bovine serum albumin (BSA) as standard.
Checkerboard assays. TPGS or -tocopherol was combined with different concentrations of nor-
ﬂoxacin, ceftazidime, or polymyxin B, and the effect of each combination was tested against the parental
B. cenocepacia K56-2, various mutant strains and their corresponding complement strains (as indicated
in Results), and also Pseudomonas aeruginosa PAO1. In the combination studies, the ﬁnal ranges of drug
dilutions used were 2 to 128 g/ml for norﬂoxacin and 2 to 512 g/ml for ceftazidime, as recommended
by the CLSI for MICs of antibiotics tested by broth microdilution (37). The ﬁnal ranges of TPGS were 0.175
to 2.8 mM, and those for liposoluble -tocopherol were 8 to 1,024 g/ml. Inocula were prepared by
diluting an overnight broth culture of each of the selected isolates in double-strength cation-adjusted
MHB to reach a ﬁnal inoculum of 5 105 CFU/ml. One honeycomb plate was used for each isolate. Each
well received 50 l of the antibiotic under test, 50 l of the vitamin E form, and 100 l of the inoculated
double-strength broth. Plates were incubated at 37°C with continuous shaking in a Bioscreen C (MTX Lab
Systems, Vienna, VA) for 24 h. The MIC endpoint was read as the lowest concentration of antibiotic at
which the percent OD600 relative to no-antibiotic control was 10%, which corresponded to no visible
growth.
In vitro antibiotic challenge assays. Challenge assays were performed as previously described (38)
with few modiﬁcations. Bacterial cultures with an OD600 of 0.0002 in MHB were challenged with MIC25
of norﬂoxacin (for 2 h) or polymyxin B (for 2 and 6 h) in either the absence or presence of 0.7 mM TPGS
and incubated at 37°C at 180 rpm. Samples were withdrawn and serially diluted in PBS. Then, 10-l
aliquots were spotted onto the surface of MH agar plates. The plates were incubated at 37°C for 24 h, and
the resulting colonies were counted.
In vitro antibiotic protection assays. Overnight cultures of the mutants (ΔbcnA, ΔbcnAB, and
ΔbcnAB ΔbcoA) in MHB were diluted to an optical density at 600 nm of 0.005 in fresh cation-adjusted
MHB containing different concentrations of norﬂoxacin and 1.5 M BcnA protein, with or without 0.7 mM
TPGS, and incubated at 37°C with medium by continuous shaking in a Bioscreen C. Bacterial growth was
assessed turbidimetrically at 600 nm. The MIC endpoint was read as the lowest concentration of
norﬂoxacin at which the percent OD600 relative to no-antibiotic control was 10%, which corresponded
to no visible growth.
Isothermal titration calorimetry. ITC experiments were performed on a MicroCal iTC200 micro-
calorimeter (Malvern, United Kingdom). The sample cell was rinsed twice with 330 l PBS (pH 7.4) before
one rinse with approximately 330 l of puriﬁed BcnA protein solution, which was left soaking for at least
2 min. The sample cell was reloaded with the protein solution (0.03 mM), and the syringe was loaded with
ligand solution (TPGS or norﬂoxacin), purged, and reﬁlled two times. Ligand concentration in the cell
ranged from 20- to 1,000-fold greater than that of protein. Run parameters were as follows: 18 injections,
initial delay of 60 s, spacing of 240 s, ﬁlter period of 5 s, injection volume of 2 l, cell temperature of 25°C,
reference power of 10 cal/s, stirring speed of 1,500 rpm, and low feedback mode. The blanks included
PBS buffer with the ligand solution. Data were analyzed with the Origin software provided by the
instrument manufacturer.
Galleria mellonella larva infection. G. mellonella larvae were acquired from UK Waxworms Ltd.,
stored in wood shavings in the dark at 16°C prior to infection, and used within 2 weeks of receipt. Larvae
of approximate weights of 250 to 350 mg were used. Larval infection assays were performed as
previously described (39, 40). Bacteria were grown in 5 ml LB, harvested during exponential phase,
resuspended in sterile PBS, and serially diluted. Larvae were injected with 10 l of the bacterial
suspension in the absence and presence of TPGS, containing approximately 8 103 CFU of either K56-2
wild type (WT) or ΔbcnA mutant or 	bcnA mutant plus 1.5 M BcnA protein, using a microliter Hamilton
syringe. A group of 10 control larvae were injected with 10 l of PBS in parallel. Larvae were incubated
at 37°C in the dark, and their viability was checked at 24-h intervals over a period of 72 h, according to
visual color change and lack of movement upon stimuli. Three independent experiments were per-
formed.
In similar assays, at 48 h postinfection, hemolymph samples were collected from 10 larvae/group
(approximately 100 l) in microcentrifuge tubes containing 50 l of a saturated solution of 1 mg/ml
N-phenylthiourea (Sigma-Aldrich, United Kingdom) and 100 l of 1% sodium deoxycholate (Sigma-
Aldrich, United Kingdom). The hemolymph was immediately serially diluted in PBS and then inoculated
on LB agar plates supplemented with spectinomycin at 100 g/ml and incubated at 37°C for 24 h, after
which colonies were counted. Three independent experiments were routinely performed.
For antibiotic treatment of infected G. mellonella larvae, overnight cultures were diluted in PBS, pH
7.4, to a ﬁnal concentration of 102 CFU of either the K56-2 or ΔbcnA strain. The larvae were injected with
10 l of the bacterial suspensions or sterile PBS (10 larvae/group in each experiment) with a Hamilton
syringe and incubated at 37°C in the dark for 24 h. Then, larvae were treated with the MIC of norﬂoxacin,
1.4 mM TPGS, or the two together and again kept at 37°C in the dark, and their viability was checked.
After 48 h postinfection, hemolymph was pooled and CFU were determined by viable count technique
using 200 g/ml spectinomycin agar. The same method was used for Galleria mellonella larvae infected
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with 10 CFU of PAO1 or K56-2 for 2 h only and then treated with the MIC of norﬂoxacin, 1.7 mM TPGS,
or the two together.
Statistical analyses. All statistical analyses were conducted with GraphPad Prism 5.0. The results are
indicated as the mean  the standard error of the mean (SEM). The paired t test was used to compare
the means of two unmatched groups. A paired t test was used to compare the means of two matched
groups. Experiments were conducted with a minimum of three biological repeats, each with at least 2
technical repeats.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
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